Latest news

Renasant Bio launches with $54.5M to tackle rare kidney disease

Renasant Bio launches with $54.5M to tackle rare kidney disease

Joachim Eeckhout
AbbVie pays $700 million upfront for a trispecific antibody from Ichnos Glenmark Innovation

AbbVie pays $700 million upfront for a trispecific antibody from Ichnos Glenmark Innovation

Joachim Eeckhout
Actithera lands $75.5M to chase next-gen cancer radiopharma

Actithera lands $75.5M to chase next-gen cancer radiopharma

Joachim Eeckhout
Merck bets $10B on COPD breakthrough with Verona Pharma buyout

Merck bets $10B on COPD breakthrough with Verona Pharma buyout

Joachim Eeckhout
Concentra snaps up troubled Cargo Therapeutics in latest biotech acquisition

Concentra snaps up troubled Cargo Therapeutics in latest biotech acquisition

Joachim Eeckhout
ProKidney’s cell therapy shows promise in chronic kidney disease trial

ProKidney’s cell therapy shows promise in chronic kidney disease trial

Joachim Eeckhout
Cogent challenges Blueprint Medicines’ Ayvakit with strong trial data for rare immune disease

Cogent challenges Blueprint Medicines’ Ayvakit with strong trial data for rare immune disease

Joachim Eeckhout
Early trial data backs AstraZeneca's $1B bet on EsoBiotec’s CAR-T therapy

Early trial data backs AstraZeneca's $1B bet on EsoBiotec’s CAR-T therapy

Joachim Eeckhout
Boston biotech industry is under pressure due to a funding drought and Trump's policy

Boston biotech industry is under pressure due to a funding drought and Trump's policy

Joachim Eeckhout
MaaT Pharma partners with Clinigen to launch Europe’s first microbiome therapy for aGvHD

MaaT Pharma partners with Clinigen to launch Europe’s first microbiome therapy for aGvHD

Joachim Eeckhout
Vyne's BET inhibitor ends psoriasis trial after FDA hold

Vyne's BET inhibitor ends psoriasis trial after FDA hold

Joachim Eeckhout
Biokin scores phase 3 win for BMS backed bispecific ADC

Biokin scores phase 3 win for BMS backed bispecific ADC

Joachim Eeckhout
FirstBack
123
Next Last